Taysha Gene Therapies Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Taysha Gene Therapies is forecast to grow earnings and revenue by 14% and 51.8% per annum respectively while EPS is expected to grow by 24% per annum.
Wichtige Informationen
14.0%
Wachstumsrate der Gewinne
24.0%
EPS-Wachstumsrate
Biotechs Gewinnwachstum | 27.1% |
Wachstumsrate der Einnahmen | 51.8% |
Zukünftige Eigenkapitalrendite | n/a |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 30 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Taysha Gene Therapies: Unjustified Sell-Off - Enough Cash Runway And Promising Rett Syndrome Data
Oct 14More Unpleasant Surprises Could Be In Store For Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Shares After Tumbling 37%
Jun 27Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky
Jun 20Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23%
Apr 20What Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) 55% Share Price Gain Is Not Telling You
Mar 21Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts
Mar 20Taysha: Produces Solid Data But Has Abandoned Programs
Feb 06Taysha Gene Therapies Gets A 'Thumbs Up'
Mar 07Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 37 | -83 | -115 | -97 | 6 |
12/31/2025 | 5 | -104 | -66 | -80 | 11 |
12/31/2024 | 8 | -89 | -75 | -61 | 12 |
6/30/2024 | 13 | -114 | -79 | -75 | N/A |
3/31/2024 | 14 | -118 | -76 | -73 | N/A |
12/31/2023 | 15 | -112 | -80 | -73 | N/A |
9/30/2023 | 14 | -214 | -52 | -42 | N/A |
6/30/2023 | 10 | -124 | -62 | -53 | N/A |
3/31/2023 | 7 | -133 | -85 | -68 | N/A |
12/31/2022 | 3 | -166 | -113 | -88 | N/A |
9/30/2022 | N/A | -161 | -174 | -143 | N/A |
6/30/2022 | N/A | -186 | -179 | -146 | N/A |
3/31/2022 | N/A | -193 | -168 | -136 | N/A |
12/31/2021 | N/A | -175 | -139 | -117 | N/A |
9/30/2021 | N/A | -142 | -116 | -97 | N/A |
6/30/2021 | N/A | -106 | -87 | -71 | N/A |
3/31/2021 | N/A | -87 | -61 | -51 | N/A |
12/31/2020 | N/A | -60 | -40 | -31 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: TSHA is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: TSHA is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: TSHA is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: TSHA's revenue (51.8% per year) is forecast to grow faster than the US market (8.9% per year).
Hohe Wachstumseinnahmen: TSHA's revenue (51.8% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if TSHA's Return on Equity is forecast to be high in 3 years time